Assessment of Immune Status in Patients with Mismatch Repair Deficiency Endometrial Cancer

Patients with MMRd-EC can be subclassified according to MutS or MutL deficiency. Patients with MutS-d exhibited better immune status, prognosis, and immunotherapy benefits than those with MutL-d. These results can help guide patients to a more precise treatment.